Monday, June 15, 2026

Defense Tech Stock VisionWave Holdings (Nasdaq: $VWAV) Files Provisional Patent for SDNN Symbiotic Neural Architecture; @VWAVInc

 

Defense Tech Stock VisionWave Holdings (Nasdaq: $VWAV) Files Provisional Patent for SDNN Symbiotic Neural Architecture; @VWAVInc


 






 

 

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV).

 

VisionWave (Nasdaq: VWAV) ,a technology company focused on advanced sensing, artificial intelligence, imaging, and autonomous technologies, today announced it files U.S. Provisional Patent Application No. 64/082,410 covering SDNN™ — Symbiotic Deep Neural Network — a proprietary neural-network architecture intended to support real-time multi-source fusion, adaptive reasoning, and coordinated control of distributed intelligent platforms across defense, security, counter-UAS, robotics, and civil infrastructure domains.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/06151-visionwave-sdnn-patent-filing.asp

 

Investorideas.com - Why is this relevant to the sector ? “According to 6Wresearch internal database and industry insights, the Autonomous Systems Market was estimated at USD 22.6 billion in 2025 and is projected to reach USD 61.3 billion by 2032, expanding at a CAGR of 14.2% during the forecast period 2026-2032.”

 

“Due to increasing adoption of automation in defense, transportation, and industrial sectors, rising demand for unmanned vehicles and drones, advancements in artificial intelligence and machine learning, and growing emphasis on efficiency, safety, and precision in complex operations are all the main factors driven by the market.”

 

In addition to the provisional patent application, VisionWave has filed a U.S. trademark application for SDNN™ as part of its broader strategy to protect the intellectual-property foundation and brand identity associated with the Company’s emerging artificial intelligence architecture. The trademark application remains subject to USPTO examination, and registration is not guaranteed.

 

The provisional patent application covers the Company’s SDNN™ — Symbiotic Deep Neural Network architecture. Internally, the Company has used the project code name “Mother” to refer to the central core layer of this architecture. SDNN™ is being developed as a proprietary AI framework intended to operate as a central reasoning and coordination layer for networks of distributed intelligent systems. The filing encompasses a 455-page specification supported by 23 engineering drawings and represents one of VisionWave’s

most comprehensive intellectual property filings to date. The filing of a provisional patent application does not guarantee the issuance of a patent or any particular scope of claims.

SDNN™ is intended to support the fusion of data from heterogeneous sensors, unmanned ground vehicles (UGVs), unmanned aerial vehicles (UAVs), satellite or external data feeds, relay nodes, and software agents. The architecture described in the filing is designed to support adaptive reasoning, confidence evaluation, coordinated tasking, and human-governed decision workflows across distributed operational networks. The Company believes SDNN™ may represent an important step in the development of multi-domain AI command-and-control and intelligent-system coordination architectures.

 

Key Technical Innovations Described in the Filing

The provisional application describes a system operating as a closed intelligence loop — Intent Reason Task Execute Feedback Adapt Repeat with the following core technology areas:

 

• Multi-source data fusion — integration of RF, radar, EO/IR, thermal, and software-agent data streams into a continuously updated operational state.

• qSpeed™ reasoning engine — a proprietary reasoning-acceleration framework intended to improve decision-cycle speed by prioritizing the most mission-critical computations first, scoring candidate reasoning tasks across dimensions such as decision relevance, urgency, risk/consequence, information gain, confidence impact, and resource cost.

• Trust quarantine architecture — trust scoring, peer-consistency checking, anomaly detection, re-attestation workflows, audit trails, and human-notification processes for distributed network nodes.

• Human-in-command governance — policy-enforced approval workflows intended to preserve human authority over consequential actions while enabling autonomous execution within pre-approved operational parameters.

• The Cube™ hardware root of trust — a compact secure hardware module with embedded encrypted software/firmware, designed to physically activate and authenticate the SDNN™ system through biometric authentication, cryptographic processing, secure memory, secure boot validation, hardware random number generation, and tamper-detection mechanisms.

• Degraded-mode resilience — adaptation protocols intended to support continuity of operation during node loss, communications degradation, or system faults.

“SDNN™ represents a fundamental rethinking of how AI can coordinate distributed intelligent systems. Rather than relying on isolated point solutions operating independently, SDNN™ is being designed with the goal of serving as a unified intelligence layer that can fuse information, reason across an operational picture, coordinate networked nodes, and learn from each mission cycle — while preserving human authority over consequential decisions.”
— Danny Rittman, Inventor and Chief Technology Architect, SDNN™

 

Broad Multi-Domain Applications

The Company believes the SDNN™ architecture, if successfully developed and validated, may address significant challenges across a range of defense and civil application domains. The provisional application describes six use case categories:

 

• Counter-UAS and anti-drone defense — fusing RF direction-finding, surveillance radar, EO/IR, and thermal sensor data to support detection, classification, tracking, and operator decision workflows related to hostile or unidentified unmanned aerial systems.

• Missile detection and interception decision-support — multi-sensor threat fusion and prioritized coordination support for low-altitude cruise and ballistic-threat environments.

• UGV-based ground confirmation — coordination of unmanned ground vehicles to corroborate uncertain detections and dynamically update situational confidence.

• Multi-robot industrial coordination — assignment, monitoring, and adaptive re-tasking of autonomous robotic systems across inspection, logistics, and manufacturing environments.

• Smart city and civil infrastructure operations — fusion of traffic, environmental, and public-safety data streams to support operational optimization and multi-agency emergency response.

• Autonomous spacecraft and long-duration mission management — conceptual applications including navigation support, crew-safety monitoring, life-support coordination, and emergency response management for autonomous space operations.

 

“The filing of the SDNN™ provisional patent application is an important milestone in VisionWave’s intellectual property strategy and our vision for AI-driven defense and autonomous systems. SDNN™ is intended to serve as a foundational architecture for multi-domain command-and-control AI, and we are committed to advancing this technology while protecting the innovation our team has developed.”
— Douglas Davis, Executive Chairman and Chief Executive Officer, VisionWave Holdings, Inc.

 

The realization of any of these use cases is subject to substantial uncertainty and will require, among other things, successful completion of research and development, product integration, and validation activities that have not yet been completed; the Company’s ability to raise significant additional capital on acceptable terms, of which there can be no assurance; successful integration of the SDNN™ architecture with third-party hardware platforms, sensor systems, and operational networks; the ability to obtain and maintain necessary regulatory, export-control, and government-security approvals; the securing of defense or commercial contracts or purchase orders, which may require lengthy procurement cycles and governmental budget authorization; achievement of market acceptance in highly competitive defense and technology markets; and the absence of unforeseen technical, operational, or geopolitical obstacles. The Company is at an early stage of development with respect to SDNN™, has not generated revenue from this architecture, and may never successfully develop or commercialize it. There can be no assurance that the SDNN™ architecture will function as intended, be completed on the contemplated timeline, or prove suitable for any of the use cases described above.

 

About the Provisional Patent Filing

The provisional application (USPTO Application No. 64/082,410) was filed on June 4, 2026 and encompasses a 455-page specification and 23 engineering drawings covering the SDNN™ system architecture, including the central SDNN™ core layer internally code-named “Mother,” The Cube™ hardware root of trust, the qSpeed™ reasoning engine, trust quarantine and governance frameworks, symbiont node lifecycle management, and multi-domain use case specifications. VisionWave Holdings, Inc. is listed as applicant-assignee. The Company has 12 months from the provisional filing date to file a corresponding non-provisional utility patent application claiming priority to this date.

 

The filing of a provisional patent application establishes a filing date and preserves the right to claim priority, but does not itself result in an issued patent and will not become a patent unless a corresponding non-provisional utility patent application is filed with the USPTO within twelve (12) months of the provisional filing date. The Company may not file such a non-provisional application on a timely basis, or at all. Even if a non-provisional application is filed, the USPTO may reject or substantially narrow the claims through examination, and there can be no assurance that any patent will be issued, that issued claims will cover the SDNN™ architecture as described or intended, or that any patent, if issued, will withstand challenge, reexamination, or invalidation proceedings. Patents, if issued, may be circumvented by competitors through design-around approaches, and the Company may lack sufficient resources to enforce its patent rights against infringers. Competitors may independently develop equivalent or superior technologies without infringing any patent the Company may obtain. The Company’s intellectual property may also be subject to claims of infringement by third parties, which could result in costly litigation, licensing obligations, or injunctions. Accordingly, there can be no assurance that any patent protection obtained, if any, will provide meaningful competitive advantage, generate revenue, or justify the costs of prosecution and enforcement.

 

The Company has also filed a U.S. trademark application for SDNN™ with the USPTO, Serial No. 99870576, covering hardware and software in the nature of a neural network and related AI/ML coordination technologies. The trademark application is pending examination, and there can be no assurance that the mark will be registered.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company's website is https://www.vwav.inc.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company’s expected development and validation of the SDNN™ architecture (internally code-named “Mother”), the potential for patent issuance and scope of claims, potential applications and competitive advantages of the technology, and the Company’s strategic initiatives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “potential,” “target,” “seek,” or similar expressions, or by statements that events, trends, or results “may,” “will,” “could,” or “should” occur or be achieved. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to: risks related to the development, integration, and testing of the SDNN™ architecture and related AI and autonomous technologies; the timing and outcome of USPTO examination of the Company’s provisional patent and trademark applications; the Company’s ability to file a timely non-provisional utility patent application; ability to secure government and defense contracts; market acceptance and competition; availability of sufficient capital and financing; intellectual property prosecution, protection, and enforcement risks; integration risks associated with recently acquired technologies and subsidiaries; delays or failures in achieving technical, development, or commercialization milestones; dependence on key personnel and strategic partners; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company’s SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

 

Contact: investors@vwav.inc

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/



Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 




Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  
https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

To UNSUBSCRIBE, Please use the SafeUnsubscribe (TM) Link below

 

 

 

 

 

 

 

 

Wednesday, June 10, 2026

Medical Tech Stock Aethlon Medical (Nasdaq: $AEMD) Reports Fiscal Year 2026 Results as Australian Oncology Study Advances to Final Dosing Cohort

 

Medical Tech Stock Aethlon Medical (Nasdaq: $AEMD) Reports Fiscal Year 2026 Results as Australian Oncology Study Advances to Final Dosing Cohort

 


 


 



 

(Investorideas.com Newswire) Investorideas.com, a trusted investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment.

 

Industry commentary:

SentimenTrader: The firm notes that healthcare has quietly demonstrated strong defensive qualities, outperforming the S&P 500 on 85% of the days the broader market posted losses of 1% or more over the past year. This resilience underscores the sector’s potential as a reliable performer during market downturns. ubs.com

 

Aethlon Medical, Inc. (Nasdaq: AEMD) Aethlon Medical, Inc. today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments.

 

Summary - Australian oncology study advances into Cohort 3 as enrollment continues

 

Entered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses.

 

 

Conference Call Today at 4:30 p.m. ET

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/06101-aemd-fiscal-year-2026-results.asp

 

Key Highlights

 

·         Advanced the Australian oncology study through completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generating data to inform future development and dosing strategy.

 

·         Recently treated the first participant in Cohort 3 at Royal North Shore Hospital in Australia. The participant completed three Hemopurifier treatments over a one-week period, marking continued enrollment momentum and execution of the study's final treatment arm.

 

·         Advanced preclinical research evaluating Hemopurifier applications in additional disease areas, including rheumatoid arthritis and chronic kidney disease, supporting the expansion of the platform's potential addressable market beyond oncology and infectious disease.

 

 

·         Continued to strengthen the intellectual property portfolio supporting the Hemopurifier platform, including the issuance of patents in the United States and Europe covering potential applications for long COVID and other coronavirus-related conditions, extending patent protection into the 2040s and enhancing long-term platform value.

         

"Fiscal 2026 was a year of meaningful execution for Aethlon as we advanced our Australian oncology study through the first two cohorts and recently initiated Cohort 3. Advancement into the final cohort represents an important clinical milestone as we work toward generating data that may help define the optimal treatment regimen and guide future development decisions. We also strengthened the Hemopurifier platform through expansion of our intellectual property portfolio and advancement of preclinical research supporting potential applications beyond oncology. Combined with our continued focus on managing operating expenses, these achievements position us to pursue multiple value-creating opportunities across our clinical and research programs." said James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical.

 

Clinical Update

Clinical Progress in Cancer Trial

 

Enrollment and treatment of participants in Cohort 2 of the Australian oncology trial have been completed. An independent Data Safety Monitoring Board reviewed the data, identified no safety concerns based on its review of available data, and recommended advancing to the third and final cohort. Screening is actively underway at the three investigative sites for this final cohort where 3-6 participants will be treated with 3 Hemopurifier sessions during a 1-week period. The first participant in Cohort 3 of the study has been enrolled and received three Hemopurifier treatments without any device deficiencies or immediate complications and is now in the follow-up period. Successful enrollment and treatment of the first participant in Cohort 3 maintains the study's clinical momentum and moves the Company closer to completing enrollment and generating data from all planned dosing regimens.

 

Serial Extracellular Vesicle and T cell measurements on participants in cohort 2 have been measured by the central lab at the University of Sydney. Formal statistical analyses comparing the effects of the three different Hemopurifier dosing regimens on these parameters will be performed by a CRO at the completion of the trial. This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®.

 

Other Recent Developments

During fiscal 2026, we strengthened our intellectual property portfolio through the issuance of patents in both the United States and Europe covering potential applications of the Hemopurifier for coronavirus-related conditions, including long COVID and other post-infection complications. These patents extend protection for certain applications of the Hemopurifier into the 2040s and further strengthen the Company's intellectual property position surrounding the Hemopurifier.

 

In addition, we advanced our preclinical extracellular vesicle (EV) research activities, including studies evaluating removal of EVs in plasma samples from patients with rheumatoid arthritis and chronic kidney disease. These efforts support the Company's ongoing evaluation of the Hemopurifier's potential applications across multiple disease categories and may create future opportunities to expand the platform into large markets characterized by significant unmet medical need.

 

Separately, we continued our evaluation of Hemopurifier compatibility with a simplified blood treatment system being developed by Stavro Medical. Initial testing assessing flow rates and transfer of fluid through the Hemopurifier has been completed, and future studies evaluating removal of surrogate markers for extracellular vesicles by the Hemopurifier using the system are under consideration. We believe this approach could expand potential treatment settings for the Hemopurifier in the future and may improve the scalability and accessibility of treatment if successfully developed and validated.

 

Subsequent to fiscal year-end, an interview published in IEEE Spectrum featuring Aethlon's Chief Medical Officer and a physician involved in the treatment of an Ebola virus disease patient with the Hemopurifier during the 2014 outbreak highlighted the Company's experience with Ebola treatment efforts. In connection with renewed public health interest surrounding recent Ebola outbreaks, we also confirmed the continued availability of our FDA-authorized expanded access (compassionate use) protocol and shared the protocol as well as past in vitro and in vivo data with organizations involved in global and U.S. emerging pathogen preparedness efforts, including the World Health Organization's R&D Blueprint expert panel and the National Emerging Special Pathogen Training and Education Center.

 

Financial Results for the Fiscal Year Ended March 31, 2026

As of March 31, 2026, the Company had approximately $5.0 million in cash and cash equivalents, providing resources to support ongoing clinical and research activities.

 

Subsequent to fiscal year-end, the Company strengthened its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program.

 

Consolidated operating expenses declined 21.9% year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company's clinical and research priorities compared to $9.3 million for the fiscal year ended March 31, 2025. The decrease was primarily due to $1.1 million reduction in payroll and related expenses, a $500,000 reduction in general and administrative expenses and a $400,000 reduction in professional fees.

 

Consistent with the reduction in operating expenses, the operating loss for the fiscal year decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year.

 

Other income was approximately $142,000 for the fiscal year ended March 31, 2026, primarily reflecting interest income earned on cash balances, compared to other expense of approximately $4 million in the prior fiscal year. The prior-year amount included approximately $4.7 million of non-cash financing-related charges.

 

Net loss attributable to our common stockholders was $7.2 million for the fiscal year ended March 31, 2026, compared to net loss of $13.4 million for the fiscal year ended March 31, 2025.

 

The consolidated balance sheets for March 31, 2026, and March 31, 2025, and the consolidated statements of operations for the fiscal years ended March 31, 2026, and 2025, are included at the end of this release.

 

Conference Call

Management will host a conference call today, Wednesday, June 10, 2026, at 4:30 p.m. ET to review the Company’s financial results and recent corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

 

Interested parties can register for the conference call by navigating to  https://dpregister.com/sreg/10209612/1042263e8ec.  Please note that registered participants will receive their dial-in number upon registration.

 

Interested parties without internet access or unable to pre-register may dial in by calling:

 

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

 

All callers should ask for the Aethlon Medical, Inc. conference call.

 

A replay of the call will be available approximately one hour after the end of the call through July 10, 2026. The replay can be accessed via Aethlon Medical’s website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 7883435.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.

 

The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for:

 

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

 

Full news and financials from AEMD

https://www.aethlonmedical.com/news-media/press-releases/detail/523/aethlon-medical-announces-fiscal-year-end-march-31-2026

 

Aethlon Medical (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical


Disclaimer/Disclosure: Aethlon Medical, Inc. is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 


Research biotech stocks at Investorideas.com

https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp

 

 

 

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Investor Ideas digital advertising and guest posts service :

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

 

Follow Investorideas and the Exploring Mining Podcast on YouTube https://www.youtube.com/c/Investorideas

 

Investors stay ahead by signing up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411

 

Tuesday, June 09, 2026

VisionWave Holdings (Nasdaq: $VWAV) Strengthens Position in AI-Based Defense Tech with Foresight Autonomous Acquisition; @VWAVInc

 

VisionWave Holdings (Nasdaq: $VWAV) Strengthens Position in AI-Based Defense Tech with Foresight Autonomous Acquisition; @VWAVInc

 



 



Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV).

VisionWave Holdings, Inc (Nasdaq: VWAV), an advanced sensing technology company developing AI-driven, RF-based sensing and computational acceleration technologies for defense and commercial uses, today announced it has executed a definitive agreement with respect to the proposed strategic acquisition of controlling interest in Foresight Autonomous Holdings Ltd. (Nasdaq: FRSX). According to the Agreement, VisionWave will acquire up to 52% of Foresight’s outstanding shares in exchange for $17.5 million in VisionWave’s shares of common stock.

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/06091-visionwave-foresight-autonomous-acquisition.asp

The global sensor market size was valued at USD 241.06 billion in 2025 and is projected to grow from USD 258.47 billion in 2026 to USD 527.94 billion by 2034

The definitive agreement with Foresight will add important sensing technology to the Company’s STRATUM™ SENSE suite of sensing technologies, and follows the Company’s latest acquisition of the xClibre™ AI video intelligence IP portfolio, which was independently valued at approximately $60 million by BDO Consulting Group as of the acquisition date for financial reporting purposes. This valuation is based on certain assumptions and methodologies and does not necessarily represent current fair market value, future realizable value, or the amount at which the assets could be sold or monetized.

Modern defense and security environments demand sensing systems that can detect, identify, classify, and act - quickly and across multiple domains simultaneously. With the definitive agreement now in place, VisionWave is positioned to deliver the architecture with enhanced performance.

RF Sensing Layer

VisionWave’s own RF-based AI detection, wide-area, all-weather threat awareness at range

Optical and Thermal Computer Vision Sensing Layer

Foresight’s camera-based stereo and thermal perception, proven across automotive and defense programs

AI Video Intelligence

xClibre™ behavioral analytics- turning existing camera infrastructure into continuously-learning AI agents

The convergence of these three layers, RF detection, multi-spectral computer vision, and AI-driven video analytics, produces a perception capability beyond what any single-modality company can deliver. RF tells you something is there. Foresight’s optics tell you where it is and how it’s moving. xClibre tells you what it’s doing and whether it is a threat.

Today, perception technology across defense and security is fragmented. RF specialists don’t build video AI. Video AI vendors don’t build RF. Autonomous systems integrators buy from multiple vendors and stitch together incompatible stacks. With this definitive agreement executed, it is VisionWave’s goal to eliminate this fragmentation and deliver a unified, superior multi-modal perception platform, for use with any UxV (Unmanned X Vehicle).

For demonstration purposes see - Foresight 3D Perception Stereoscopic Visible Light vs. Thermal video:

Merging visible light cameras and thermal LWIR cameras.



Rendering of segmentation and detection

TRANSACTION SUMMARY

Under the agreement, VisionWave will acquire a controlling interest of up to 52% stake in Foresight through a two-stage share exchange: 46% of Foresight’s issued and outstanding ordinary shares upon Stage 1 Closing (expected within 45-60 days), with the right to an additional 6% upon achievement of a defined commercial milestone - the commencement of a binding pilot project integrating the Perception Platform in the commercial, defense, or security sector. In exchange, VisionWave will issue newly issued shares of its common stock with an aggregate value of approximately $17.5 million (calculated based on the five-day volume-weighted average price preceding each closing), plus up to $3 million in management equity grants. VisionWave will also gain significant board representation, with the right to designate two directors to Foresight’s Board upon Stage 1 Closing and one additional director upon Stage 2 Closing.  The transaction remains subject to customary closing conditions, including regulatory approvals, Nasdaq listing requirements (if applicable), and any required shareholder approvals.

Both companies will continue to operate as independent, publicly traded entities. The transaction positions VisionWave to establish its core operating platform for RF-focused perception systems and related defense, security, and autonomous technology initiatives by integrating Foresight’s high-resolution visible light/infra-red and neuromorphic event-based sensor suite.

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company’s website is https://www.vwav.inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the execution and closing of the transaction with Foresight Autonomous Holdings Ltd., the expected benefits of the acquisition, integration of technologies into the STRATUM™ SENSE suite, achievement of commercial milestones, anticipated board representation, operational synergies, and the Company’s strategic initiatives in defense and security sensing. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are generally identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," and similar expressions, or by statements that events or trends "may," "will," or "could" occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to, risks related to the completion of the transaction on the proposed terms or at all (including failure to obtain required approvals or satisfy closing conditions), integration challenges, dilution from equity issuance, market volatility affecting VWAV share price used for consideration, regulatory scrutiny of the acquisition, technological development risks, competition in the defense sector, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company's SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contact: investors@vwav.inc

 

Watch recent VWAV video

https://www.youtube.com/shorts/wr4R7VSy7VM

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/



Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp




Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas